Indian Pharma sees robust growth of 51.5 percent in April sales: AIOCD-AWACS Report

The report further included that gastrointestinal drugs grew at a faster rate of 56.8% in April 2021 compared to 21.6% per cent in March 2021. The Respiratory domain, meanwhile, grew at a faster pace of 49.7% in April 2021 compared to 22.2% in March 2021.

Furthermore, pain/analgesics, neuro/CNS drugs, gynecological, antineoplastic, hormones, and opthal/otologicals grew at 64.2%, 21.3% ,47.0% ,38.7% ,54.5% ,37.6% respectively. 

Considering the market performance, the study said, "Companies operating in Covid treatment therapy segments have gained substantially through bumper sales for the month."

However, based on sales results, Glenmark's Fabiflu, an antiviral medication Favipiravir that is widely prescribed in Covid 19, dominated the list of highest-selling products this month, followed by USV Private Limited's Glycomet GP, a fixed dosage mixture of Glimepride and Metformin, and Abbott's Mixtard, a human premix Insulin.

Cipla topped the top ten list with a MAT corporate growth of 13.6 percent in the month of April 21, with bonus units at full value, according to the report, followed by Intas with a MAT corporate growth of 8.2 percent.

Similarly, Glenmark had the highest MAT corporate growth percentage of approximately 29 percent among the 11 to 25 ranked corporates in the month of April 21, accompanied by Himalaya with a MAT corporate growth percentage of 18.55 percent.